RU2016107378A3 - - Google Patents

Download PDF

Info

Publication number
RU2016107378A3
RU2016107378A3 RU2016107378A RU2016107378A RU2016107378A3 RU 2016107378 A3 RU2016107378 A3 RU 2016107378A3 RU 2016107378 A RU2016107378 A RU 2016107378A RU 2016107378 A RU2016107378 A RU 2016107378A RU 2016107378 A3 RU2016107378 A3 RU 2016107378A3
Authority
RU
Russia
Application number
RU2016107378A
Other languages
Russian (ru)
Other versions
RU2016107378A (ru
RU2734760C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016107378A publication Critical patent/RU2016107378A/ru
Publication of RU2016107378A3 publication Critical patent/RU2016107378A3/ru
Application granted granted Critical
Publication of RU2734760C2 publication Critical patent/RU2734760C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016107378A 2013-08-02 2014-08-01 Противоинфекционные соединения RU2734760C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361861750P 2013-08-02 2013-08-02
US61/861,750 2013-08-02
PCT/EP2014/066614 WO2015014993A2 (en) 2013-08-02 2014-08-01 Anti-infective compounds

Publications (3)

Publication Number Publication Date
RU2016107378A RU2016107378A (ru) 2017-09-07
RU2016107378A3 true RU2016107378A3 (enExample) 2018-03-29
RU2734760C2 RU2734760C2 (ru) 2020-10-23

Family

ID=51260879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016107378A RU2734760C2 (ru) 2013-08-02 2014-08-01 Противоинфекционные соединения

Country Status (12)

Country Link
US (1) US20160185774A1 (enExample)
EP (1) EP3027615B1 (enExample)
JP (3) JP2016525562A (enExample)
KR (1) KR102292293B1 (enExample)
CN (2) CN109575018A (enExample)
DK (1) DK3027615T3 (enExample)
ES (1) ES2883565T3 (enExample)
HU (1) HUE056198T2 (enExample)
PH (1) PH12016500207A1 (enExample)
RU (1) RU2734760C2 (enExample)
SG (1) SG11201600686QA (enExample)
WO (1) WO2015014993A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017001660A1 (en) 2015-07-02 2017-01-05 Janssen Sciences Ireland Uc Antibacterial compounds
AU2016324598A1 (en) 2015-09-17 2018-03-15 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
JP2019518046A (ja) * 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
JP2019518050A (ja) * 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
WO2018158280A1 (en) 2017-03-01 2018-09-07 Janssen Sciences Ireland Uc Combination therapy
US11129816B2 (en) 2017-10-05 2021-09-28 Quretech Bio Ab Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
CN108101828B (zh) * 2018-01-15 2021-05-04 西华师范大学 3-吲哚基甲酰胺类化合物及其制备方法
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JPWO2020203609A1 (enExample) * 2019-03-29 2020-10-08
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
TWI861208B (zh) * 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2022003814A (es) * 2019-09-30 2022-05-06 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos de 4-quinolinona.
CA3151712A1 (en) * 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
KR102381397B1 (ko) * 2020-07-10 2022-03-30 경희대학교 산학협력단 신규 나프토퀴논 유도체 화합물 및 이를 포함하는 항균용 조성물
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
CN117440958A (zh) * 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
CN118159543A (zh) 2021-10-28 2024-06-07 爱尔兰詹森科学公司 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
US20100298314A1 (en) * 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
WO2009140101A2 (en) * 2008-05-12 2009-11-19 Boehringer Ingelheim International Gmbh Imidazopyridine compounds useful as mmp-13 inhibitors
EP2496578A4 (en) * 2009-11-05 2013-08-21 Univ Notre Dame Du Lac IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
AU2011229423B2 (en) * 2010-03-18 2015-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-infective compounds
US9029389B2 (en) * 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
CN103324035B (zh) * 2013-06-20 2015-07-01 深圳市华星光电技术有限公司 掩膜板和阵列基板的制作方法

Also Published As

Publication number Publication date
SG11201600686QA (en) 2016-02-26
JP2018158941A (ja) 2018-10-11
EP3027615B1 (en) 2021-07-21
RU2016107378A (ru) 2017-09-07
JP2019131606A (ja) 2019-08-08
KR20170082450A (ko) 2017-07-14
DK3027615T3 (da) 2021-10-25
WO2015014993A3 (en) 2015-04-02
PH12016500207A1 (en) 2016-04-25
JP2016525562A (ja) 2016-08-25
HUE056198T2 (hu) 2022-02-28
JP6757768B2 (ja) 2020-09-23
EP3027615A2 (en) 2016-06-08
KR102292293B1 (ko) 2021-08-23
ES2883565T3 (es) 2021-12-09
CN109575018A (zh) 2019-04-05
WO2015014993A2 (en) 2015-02-05
CN105745208A (zh) 2016-07-06
RU2734760C2 (ru) 2020-10-23
US20160185774A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112015007533A2 (enExample)
BR112014018502A2 (enExample)
BR112016001143A2 (enExample)
BR112014019326A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112016003819A2 (enExample)
BR112014020341A2 (enExample)
BR112014021878A2 (enExample)
RU2016107378A3 (enExample)
BR112016005365A2 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112016013278A2 (enExample)
BR112015019515A2 (enExample)
BR112016015033A2 (enExample)
BR112016003520A2 (enExample)
BR112016000485A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112016000122A2 (enExample)
BR112016012407A2 (enExample)